Resources

The government's plan to put life sciences up in lights this Sunday ahead of the International investment Summit was somewhat overtaken by the news of the reorganisation of Keir Starmer's Number 10 team which dominated headlines. Nevertheless, it's been a busy week of announcements affecting our sector.

The BIA’s policy and public affairs team attended the conferences of the three major UK parties this year. This is a key point in the political calendar and allows us to highlight the sector through fringe events, meet policymakers, and get a sense of the political environment.

Ingenza, a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator, has signed a 10-year lease at the Moubray Building at Edinburgh Technopole, part of Pioneer Group.

Dr Peter Bloomfield is the Director of Research at the Macular Society. In this guest blog, he lays out the problem posed by macular disease and his hope for a solution. He also gives insight into why the Macular Society joined the BIA.

London, October 3, 2024 – Coulter Partners recently partnered with MTIP and the Nitinotes Board to conduct a successful search for a new Chief Executive Officer (“CEO”) for Nitinotes.

Cancer Research UK and NovalGen have signed an agreement to bring NovalGen’s next-generation T-cell engager, NVG-222, into a first-in-human clinical trial.

Enara Bio announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors.

The UK’s first network of cystic fibrosis innovation hubs is being launched to accelerate the development of new diagnostic tools and therapeutic approaches to detect, treat and manage lung infections.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, recaps the recent Women in Biotech event in Manchester, where industry leaders discussed talent attraction, female leadership, and career advancement. The panel highlighted the importance of fostering home-grown talent, supporting female role models, and offering mentorship opportunities.

The BioIndustry Association, in partnership with the CPI, is today publishing a new report - mRNA Revolution: A new generation of medicine. 

The shape of the political landscape that our sector will navigate this year became clear at the Labour Party conference in Liverpool last week. The new Labour government will unveil its industrial strategy, hold a Global Investment Summit, and meet with the Life Science Council before the key moment of the Budget on 30 October.

Laverock Therapeutics announced significant progress in the industrialisation and validation of its technology platform enabling broadening of its potential therapeutic application.

In this blog, the BIA's Senior Policy and Public Affairs Manager, Dr Emma Lawrence, discusses the life science implications of Lord Darzi's review.

PACE has launched its second funding round, with up to £5 million available to support cutting-edge diagnostic projects. This funding is part of a broader £30 million investment to address the global challenge of AMR.

London, September 26, 2024 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with CellCentric and is pleased to announce the placement of Andy Fergus as Chief Development Officer. Andy joined CellCentric in September 2024, and is Boston based.